SCHEMBL18264153

SCHEMBL18264153

Cc1cccc2c1nc(Cl)c1c(N)n[nH]c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 2/20 0.47
FLT3 P36888 1/20 0.47
PLK3 Q9H4B4 1/20 0.47
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
RAD52 P43351 2/20 0.40
PSMD14 O00487 1/20 0.40
MITF O75030 1/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
APEX1 P27695 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GAA P10253 1/20 0.40
PARP1 P09874 2/20 0.38
MAP4K4 O95819 1/20 0.38
CSF1R P07333 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21670127 0.79 TRPA1 (0.42) CHEK1FLT3PLK3KDM4EALDH1A1
SCHEMBL18264145 0.76 CHEK1 (0.49) CHEK1FLT3PLK3KDM4EALDH1A1
SCHEMBL20423193 0.76 MEN1 (0.47) FLT3KDM4ELMNAPOLBMAPT
SCHEMBL3654198 0.74 CHEK1 (0.62) CHEK1FLT3PLK3KDM4EALDH1A1
SCHEMBL11606052 0.68 HRH4 (0.44) KDM4EALDH1A1RAD52PSMD14MITF
SCHEMBL21790697 0.68 HRH4 (0.51) KDM4EALDH1A1RAD52PSMD14MITF
SCHEMBL18264172 0.68 PIM1 (0.43) CHEK1FLT3PLK3ALDH1A1LMNA
SCHEMBL10810254 0.68 ELANE (0.44) KDM4EALDH1A1RAD52PSMD14MITF
SCHEMBL11060868 0.66 KDM4E (0.61) KDM4EALDH1A1RAD52PSMD14MITF
SCHEMBL18264146 0.66 ACHE (0.40) CHEK1FLT3PLK3MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3302060-B1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE UNIV KAOHSIUNG MEDICAL (TW) 2020-02-12 EP claimed
US-20180214426-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE KAOHSIUNG MEDICAL UNIVERSITY (TW) 2018-08-02 US claimed
EP-3302060-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE Kaohsiung Medical University (TW) 2018-04-11 EP claimed
WO-2016191576-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE DCB-USA LLC (US) 2016-12-01 WO claimed
EP-3662751-B1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF B-GLUCURONIDASE UNIV KAOHSIUNG MEDICAL (TW) 2021-10-13 EP disclosed
US-11135206-B2 Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase KAOHSIUNG MEDICAL UNIVERSITY (TW) 2021-10-05 US disclosed
US-11052072-B2 Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase KAOHSIUNG MEDICAL UNIVERSITY (TW) 2021-07-06 US disclosed
EP-3662751-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF B-GLUCURONIDASE Kaohsiung Medical University (TW) 2020-06-10 EP disclosed
US-20200113878-A1 PYRAZOLO[4,3-C]Quinoline Derivatives For Inhibition Of Beta-Glucuronidase KAOHSIUNG MEDICAL UNIVERSITY (TW) 2020-04-16 US disclosed
EP-3302060-B1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE UNIV KAOHSIUNG MEDICAL (TW) 2020-02-12 EP disclosed
US-20180214426-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE KAOHSIUNG MEDICAL UNIVERSITY (TW) 2018-08-02 US disclosed
EP-3302060-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE Kaohsiung Medical University (TW) 2018-04-11 EP disclosed
CN-107708419-A Pyrazolo [4,3-c ] quinoline derivatives having inhibitory activity on bacterial glucuronidase 高雄医学大学 2018-02-16 CN disclosed
WO-2016191576-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE DCB-USA LLC (US) 2016-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180214426-A1 PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF BETA-GLUCURONIDASE UGT1A3, UGT1A1, GUSB CHEK1 669/4885FLT3 696/4885PLK3 783/4885
US-20200113878-A1 PYRAZOLO[4,3-C]Quinoline Derivatives For Inhibition Of Beta-Glucuronidase UGT1A3, UGT1A1, GUSB CHEK1 669/4885FLT3 696/4885PLK3 783/4885
US-11052072-B2 Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase UGT1A3, UGT1A1, DPP3 CHEK1 659/4885FLT3 626/4885PLK3 837/4885
US-11135206-B2 Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase UGT1A3, UGT1A1, DPP3 CHEK1 659/4885FLT3 626/4885PLK3 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.